Toggle light / dark theme

Regardless, the coming year promises — for now, at least — a slew of hotly anticipated new buildings, from Africa’s tallest skyscraper to a futuristic water bottling factory in Italy.

Notable for their design, potential cultural impact or the conversations they are likely to generate, here are nine architecture projects to look forward to.

The process took eight days to complete.

Five thin-as-human-hair plastic sheets coated with reflective material that will protect the James Webb Space Telescope (JWST) have now been successfully deployed, the National Aeronautics and Space Agency (NASA) said in its press release.

Ever since its launch on Christmas Day, space enthusiasts were eager to know if the sunshield on the JWST that is designed to protect the sensitive instruments on board would be deployed to perfection. To rightfully take the place of the mighty Hubble, the JWST has to overcome its 344 potential points of failure, and deploying the sunshield is a major achievement.

And it claims any roofer can install its new solar shingles.

GAF Energy, a division of roofing giant GAF, developed new solar shingles that are so easy to install no special equipment or knowledge is required, a TechCrunch report reveals.

The new accessible home renewable energy option provides serious competition for Tesla, who revealed their own new tiles with 22 percent more energy capacity last month.

Solar shingles have traditionally been difficult to install, as they replace traditional shingles to act as roofing material and solar cells at the same time. Tesla’s solar roofs, for example, require a special team to carry out what is essentially a whole roof replacement that has, in the past, taken weeks to complete.

With its new solar shingles, GAF Energy hopes to make installation easier and more flexible. Not only will it allow quicker install times, but it will also allow specific patches of roofing to be replaced with solar shingles, meaning customers won’t only have the option of replacing their entire roof.

The new SSDs have read/write speeds up to 14/12GBps.

For the first time in two years, XPG is on location in Las Vegas for the 2022 CES show, revealing ‘Dawn of a New Xtreme’. Under the new theme, the latest products from XPG and ADATA including gaming systems, peripherals, accessories, and components were unveiled. The highlight, however, is the PCIe (peripheral component interconnect express) 5.0 solid-state drives (SSD), the super-fast solid storage that is capable of read/write speeds up to 14/12GBps.

Twice as fast as the fastest PCIe 4.0 drives, Adata introduced two prototypes of its first PCIe 5.0 NVMe M.2 SSDs with capacities up to 8TB. The so-called Project Nighthawk SSD is designed using a Silicon Motion SM2508 controller capable of sequential read/write speeds up to 14/12GBps, while the Project Blackbird SSD features an InnoGrit IG5666 controller for 14/10GBps read/write speeds.

Hackers breached the computer networks of a southeast Florida health care system in October and may have accessed sensitive personal and financial information on over 1.3 million people, the health care system announced this week.

Social Security numbers, patient medical history and bank account information are among the data that have been exposed in the breach of Broward Health, a network of over 30 health care facilities serving patients across roughly 2 million-person Broward County, Florida, according to a notice the health care provider filed with the Office of the Maine Attorney General.

About 470 of the data breach victims live in Maine. Like other states, Maine law requires organizations that hold state residents’ personal data to file a disclosure when they’ve been hacked.

A cheap, widely available drug used to treat mental illness cuts both the risk of death from COVID-19 and the need for people with the disease to receive intensive medical care, according to clinical-trial results1. The drug, called fluvoxamine, is taken for conditions including depression and obsessive-compulsive disorder. But it is also known to dampen immune responses and temper tissue damage, and researchers credit these properties with its success in the recent trial. Among study participants who took the drug as directed and did so in the early stages of the disease, COVID-19-related deaths fell by roughly 90% and the need for intensive COVID-19-related medical care fell by roughly 65%.


Study co-author Angela Reiersen, a psychiatrist at Washington University School of Medicine in St Louis, Missouri, has long been interested in using fluvoxamine to treat a rare genetic condition. While monitoring the fluvoxamine literature before the pandemic, she came across a 2019 study showing that fluvoxamine reduced inflammation in mice with sepsis2. When COVID-19 hit, “I immediately thought back to that paper with the mice,” she says.

Reiersen and her colleagues partnered with the organizers of the TOGETHER Trial, which aims to identify approved drugs that can be repurposed to treat COVID-19. The team’s study included 1,497 people in Brazil who had COVID-19 and were at high risk of severe disease. Roughly half received fluvoxamine, and the rest received a placebo.

The trial’s results, published on 27 October, mean that fluvoxamine is one of a handful of therapies that show strong evidence of preventing progression from mild to severe COVID-19. The only early-stage treatments currently recommended by the US National Institutes of Health are monoclonal antibodies, which are costly and difficult to administer in an outpatient setting.